Insmed Option Alert: May 16 $72.5 Puts at the Bid: 2971 vs 26 OI; Earnings 5/8 Before Open [est] 

Insmed Option Alert: May 16 $72.5 Puts at the Bid: 2971 @ $4.4 vs 26 OI; Earnings 5/8 Before Open [est] Ref=$72.735

Insmed Option Alert: May 16 $72.5 Puts at the Bid: 3964 vs 26 OI; Earnings 5/8 Before Open [est] 

Insmed Option Alert: May 16 $72.5 Puts at the Bid: 3964 @ $4.4 vs 26 OI; Earnings 5/8 Before Open [est] Ref=$73.34

Insmed (NASDAQ:INSM) Bolsa

INSMED INC

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Inc

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 6.26% on an annualized basis producing an average annual return of 20.05%. Currently, Insmed has a market capitalization of $12.09 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 5 years ago, it would be worth $265.55 today based on a price of $66.36 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748472314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

INSM

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 4.37% since its last report. The company recently reported that it has 15.78 million shares sold short, which is 8.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.09 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748008828_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.26%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Insmed?

&nbsp; Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE&#xAE;, TPIP and Health Economics and Outcomes Research &nbsp;&nbsp;—
&nbsp;Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, which took place May 18-21 in San Francisco, including three prespecified subgroup analyses from the Phase 3 ASPEN trial of brensocatib in non-cystic fibrosis bronchiectasis (NCFBE), signaling the consistency of efficacy and safety outcomes across diverse clinical profiles.
"It is critical that we understand not only how brensocatib performed across the full ASPEN population, but also how it works within individual subgroups," said James D. Chalmers, MBChB, Ph.D., Professor of Respiratory Research, University of Dundee. "These new analyses offer evidence of consistent efficacy and safety in key patient types—including adolescents aged 12 and older, those receiving macrolide therapy, and individuals with various blood eosinophil levels—reinforcing the potential of brensocatib as a foundational treatment for this complex and heterogeneous disease."
ASPEN Study Prespecified Subgroup Analyses Three prespecified subgroup analyses from ASPEN showed brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and reduced lung function decline compared with placebo with a similar safety profile as the overall trial in the following populations:
<ul>
<li>Adolescents: In adolescents, brensocatib 10 mg and 25 mg reduced annualized exacerbation rates vs placebo (annualized rates: 0.35 and 0.64 vs 0.87), with 59% of patients in both dose groups remaining exacerbation-free vs 35% on placebo. Adolescent patients also experienced improvements in lung function as measured by forced expiratory volume in 1 second (FEV₁), while on either dose of brensocatib, while patients in the placebo group experienced FEV1 decline.</li>
<li>Maintenance macrolide use: Brensocatib demonstrated efficacy in patients regardless of maintenance use of macrolides (without vs with). Annualized exacerbation rates were lower with brensocatib (10 mg: 0.97/1.21; 25 mg: 0.98/1.21) vs placebo (1.23/1.54), and a greater proportion remained exacerbation-free across subgroups. Brensocatib 25 mg also reduced FEV₁ decline in both subgroups.</li>
<li>Blood eosinophil level: Brensocatib 10 mg and 25 mg reduced annualized exacerbation rates, prolonged the time to first exacerbation, and increased the odds of remaining exacerbation-free in both subgroups of patients with high (≥300/mm3) or low (&lt;300/mm3) blood eosinophil counts at baseline. Brensocatib 25-mg reduced lung function decline and numerically improved Quality of Life-Bronchiectasis Respiratory Symptoms Domain score (QOL-B RSS) at week 52 vs placebo regardless of baseline blood eosinophil count.</li>
</ul>
"These new analyses from ASPEN—the largest Phase 3 trial in bronchiectasis to date—demonstrated consistent efficacy and safety across three key patient groups, reinforcing the potential of brensocatib to deliver meaningful clinical benefit where no approved treatments currently exist," said Martina Flammer, M.D., Ph.D., Chief Medical Officer of Insmed. "The breadth and depth of our scientific contributions at ATS across our respiratory portfolio reflect our commitment and deep pride in advancing research that has the potential to transform care for patients with serious diseases."

Biotech

General

Insmed Incorporated Announces It Presented 11 New Abstracts At The American Thoracic Society 2025 International Conference, Including Three Prespecified Subgroup Analyses From The Phase 3 Aspen Trial Of Brensocatib In Non-cystic Fibrosis Bronchiectasis

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Kelly Shi initiated coverage on Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announced a price target of $105. Insmed shares closed at $67.75 on Monday. <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Black Hills Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) with an Outperform rating and announced a price target of $68. Black Hills shares closed at $58.07 on Monday. <a href="https://www.benzinga.com/quote/BKH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Evergy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with an Outperform rating and announced a price target of $75. Evergy shares closed at $65.35 on Monday. <a href="https://www.benzinga.com/quote/EVRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Market Perform rating and announced a price target of $46. Portland Gen Electric shares closed at $42.62 on Monday. <a href="https://www.benzinga.com/quote/POR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Pinnacle West Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Market Perform rating and announced a price target of $95. Pinnacle West Capital shares closed at $90.07 on Monday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying INSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-1024x601.png" alt="" class="wp-image-913464" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145.png 1076w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Initiation

Markets

Analyst Ratings

EVRG

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Jefferies analyst Kelly Shi initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $105.

Price Target

Jefferies Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $105

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $99.0, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 2.86% from the previous average price target of $96.25.
<img src="https://www.benzinga.com/files/images/story/2025/1747051252_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Insmed by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Insmed. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Insmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insmed's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insmed analyst ratings.</a>
<h2>About Insmed</h2>
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
<h3>Insmed: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Insmed displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 22.94%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Insmed's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -276.42%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Insmed's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -133.45%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Insmed's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.41%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Insmed's debt-to-equity ratio surpasses industry norms, standing at 11.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Insmed's Future

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

UBS Maintains Buy on Insmed, Lowers Price Target to $109

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 6.96% on an annualized basis producing an average annual return of 21.46%. Currently, Insmed has a market capitalization of $11.88 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 5 years ago, it would be worth $2,648.68 today based on a price of $65.63 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746808300_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

WIIM

Insmed shares are trading lower after the company reported worse-than-expected Q1 earnings and reaffirmed full-year guidance below estimates.

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) affirms FY2025 sales outlook from $405.00 million-$425.00 million to $405.00 million-$425.00 million vs $467.80 million estimate.

Guidance

Insmed Affirms FY2025 Sales Guidance of $405.00M-$425.00M vs $467.80M Est

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.42) per share which missed the analyst consensus estimate of $(1.33) by 6.77 percent. This is a 33.96 percent decrease over losses of $(1.06) per share from the same period last year. The company reported quarterly sales of $92.82 million which beat the analyst consensus estimate of $92.08 million by 0.81 percent. This is a 22.94 percent increase over sales of $75.50 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Insmed Q1 EPS $(1.42) Misses $(1.33) Estimate, Sales $92.82M Beat $92.08M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$42.00</td>
<td>$31.6K</td>
<td>1.4K</td>
<td>3.6K</td>
</tr>
<tr>
<td>ALDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.50</td>
<td>$62.2K</td>
<td>973</td>
<td>2.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$83.00</td>
<td>$187.0K</td>
<td>24</td>
<td>1.0K</td>
</tr>
<tr>
<td>KNSA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$20.00</td>
<td>$42.7K</td>
<td>308</td>
<td>299</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$41.0K</td>
<td>5.0K</td>
<td>286</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.00</td>
<td>$30.0K</td>
<td>5.1K</td>
<td>200</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$72.50</td>
<td>$31.9K</td>
<td>2.7K</td>
<td>197</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$77.4K</td>
<td>29.7K</td>
<td>115</td>
</tr>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$27.1K</td>
<td>434</td>
<td>104</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$480.00</td>
<td>$50.9K</td>
<td>849</td>
<td>63</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bullish, expiring in 4 day(s) on May 9, 2025. This event was a transfer of 80 contract(s) at a $42.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $395.0 per contract. There were 1486 open contracts at this strike prior to today, and today 3666 contract(s) were bought and sold. 
• For ALDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 1778 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $62.2K, with a price of $35.0 per contract. There were 973 open contracts at this strike prior to today, and today 2028 contract(s) were bought and sold. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on May 23, 2025. Parties traded 1000 contract(s) at a $83.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $187.0K, with a price of $187.0 per contract. There were 24 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• Regarding KNSA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>), we observe a call option sweep with bullish sentiment. It expires in 74 day(s) on July 18, 2025. Parties traded 50 contract(s) at a $20.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $42.7K, with a price of $855.0 per contract. There were 308 open contracts at this strike prior to today, and today 299 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bullish, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 79 contract(s) at a $80.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $41.0K, with a price of $520.0 per contract. There were 5034 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a call option trade that happens to be bearish, expiring in 137 day(s) on September 19, 2025. This event was a transfer of 200 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $150.0 per contract. There were 5132 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be neutral, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 49 contract(s) at a $72.50 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $658.0 per contract. There were 2748 open contracts at this strike prior to today, and today 197 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a put option sweep with bullish sentiment. It expires in 256 day(s) on January 16, 2026. Parties traded 113 contract(s) at a $30.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $77.4K, with a price of $686.0 per contract. There were 29726 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold. 
• For CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 28 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $27.1K, with a price of $970.0 per contract. There were 434 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on May 16, 2025. Parties traded 7 contract(s) at a $480.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $50.9K, with a price of $7280.0 per contract. There were 849 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALDX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KNSA

10 Health Care Stocks Whale Activity In Today's Session

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 4.19% since its last report. The company recently reported that it has 15.12 million shares sold short, which is 8.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746126028_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Insmed Gaining or Losing Market Support?

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 3.02% on an annualized basis producing an average annual return of 13.16%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $3,284.86 today based on a price of $67.90 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745591414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Insmed Reveals Redemption Of All $569.5M Of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo—
—Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Decline—
—Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration—
BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM). The landmark ASPEN study is the largest clinical trial ever conducted in bronchiectasis, a serious, chronic, and progressive inflammatory pulmonary disease that today has no approved therapies.

Insmed Announces New England Journal Of Medicine Publishes Results From Its Pivotal Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis; Largest Global Clinical Trial Ever Conducted In Bronchiectasis Demonstrates Statistically Significant And Clinically Meaningful Reduction In Frequency Of Pulmonary Exacerbations Versus Placebo

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) stock jumped 22.55% &nbsp;after it announced a strategic partnership with Cobalt Service Partners to power 12 commercial access solutions brands with<a href="https://www.benzinga.com//node/44817937" target="_blank" rel="noreferrer noopener"> its business management software</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares were up 22.13%.</li>
<li>YPF Sociedad Anonima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) shares increased 19.94% after HSBC analyst Liyanna Yang upgraded the stock from Reduce to Hold and raised the <a href="https://www.benzinga.com/quote/ypf/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$21&nbsp;to&nbsp;$33</a>.</li>
<li>Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;stock rose 16.51% after the U.S. healthcare giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control <a href="https://www.benzinga.com//node/44860903" target="_blank" rel="noreferrer noopener">with&nbsp;diet and exercise alone</a>.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares grew 16.47%  after the company hinted it might resume purchasing Bitcoin (CRYPTO: BTC/USD) <a href="https://www.benzinga.com//node/44789931">after a week-long pause</a>.</li>
<li>America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>)&nbsp;stock upped 15.88% after HSBC analyst Madhvendra Singh upgraded the stock from Hold to Buy and raised <a href="http://benzinga.com/quote/amx/analyst-ratings" target="_blank" rel="noreferrer noopener">its price forecast from&nbsp;$15.5&nbsp;to&nbsp;$17.5</a>.</li>
<li>Ericsson&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares upped 14.91% after the company reported&nbsp;first-quarter results. Additionally, the company and Bell Canada announced the successful test of AI-native link adaptation to <a href="https://www.benzinga.com//node/44823834" target="_blank" rel="noreferrer noopener">boost network speed and efficiency</a>.</li>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) stock rose 12.10%.</li>
<li>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) stock surged 11.76% after Truist Securities analyst Neal Dingmann&nbsp;raised its price forecast from&nbsp;$238&nbsp;to&nbsp;$242&nbsp;<a href="https://www.benzinga.com/quote/fang/analyst-ratings" target="_blank" rel="noreferrer noopener">and maintained a Buy rating</a>.</li>
<li>Neurocrine Biosciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)&nbsp;shares increased 11.75% after some <a href="https://www.benzinga.com//node/44818760" target="_blank" rel="noreferrer noopener">analysts upgraded the stock</a>.</li>
</ol>
Photo by DCStockPhotography via Shutterstock

Equities

Large Cap

Movers

ERIC

FANG

MSTR

NBIX

SMMT

TTAN

In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?

Press Releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Offerings

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Insmed To Present at the BofA Securities 2025 Health Care Conference

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Comments

Insmed

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
02:46 PMApr 01, 2025	PUT	$72.50	May 16, 2025	-22	4033	2971	15512	26	TRADE	BULLISH
02:38 PMApr 01, 2025	PUT	$72.50	May 16, 2025	-22	5025	3964	19327	26	TRADE	NEUTRAL